Last updated: May 21, 2026
Lusedra (Daprodustat) clinical trials update, market analysis, and exclusivity-driven projection
Lusedra is a brand for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used for anemia in chronic kidney disease. Current public information is insufficient to produce a complete, jurisdiction- and date-accurate clinical-trials update, detailed Orange Book status, and an exclusivity-backed revenue projection without risking incorrect milestones or patent dates.
What clinical trials have evaluated Lusedra (daprodustat), and what are the latest results?
Featured snippet answer: No complete, verifiable “latest trial update” set is available in the provided context.
Which Phase 3 efficacy endpoints were used for daprodustat in CKD anemia?
Common Phase 3 endpoints for hypoxia-inducible factor (HIF-PHI) programs include:
- Hemoglobin maintenance and response rates
- RBC transfusion avoidance
- Safety signals including cardiovascular outcomes and mortality composites
What safety issues are most scrutinized for daprodustat
HIF-PHIs are evaluated for:
- Thromboembolic events
- Hypertension
- VTE risk signals
- Cardiovascular outcomes and overall survival in CKD populations
How do ongoing trials typically split by CKD stage and dialysis status
Programs usually stratify by:
- Dialysis vs non-dialysis CKD
- Baseline anemia severity and ESA use history
- Conversion cohorts (switching from ESA to HIF-PHI)
What patents protect Lusedra (daprodustat), and how many are in the estate?
Featured snippet answer: No patent list, expiration dates, or jurisdictions are provided in the supplied context.
Patent estate map needed for litigation and launch planning
A complete estate map for daprodustat would require, at minimum:
- Active ingredient composition of matter patents
- Salt/crystal and polymorph patents
- Formulation patents (tablet composition, coatings, release)
- Method-of-use patents for CKD anemia dosing and hemoglobin targets
- Manufacturing process patents
How to count patents by jurisdiction
Launch risk differs by:
- FDA-listed US patents and expiration dates (Orange Book)
- EU patent coverage (EP family coverage and national validation)
- UK and other mapped jurisdictions for commercial manufacturing and sales
When does Lusedra (daprodustat) lose exclusivity for US launches and biosimilar-style risks?
Featured snippet answer: No exclusivity timeline is provided in the supplied context.
What matters for exclusivity timing in the US
For small-molecule drugs like daprodustat, the controlling items for generic entry planning typically include:
- Patent expiration of FDA-listed patents
- Non-patent exclusivities (if any) and data exclusivity windows
- Switching/labeling exclusivity is usually less central than patent expiration for generics
Paragraph IV challenges and settlement-driven timing
A complete timing model needs:
- First PIV filing date(s)
- Court decision dates or appeal windows
- Stated settlement entry “carve-outs” or “no-early-entry” commitments
What is the Orange Book status of Lusedra (daprodustat)?
Featured snippet answer: Orange Book status is not provided in the supplied context.
What the Orange Book listing must include
To support a defensible “status” answer, the listing must be enumerated with:
- Patent numbers
- Patent expiration dates
- Listed drug product (strength, dosage form)
- Patent submission type (drug substance vs drug product vs method of use)
- Regulatory exclusivity codes, if applicable
Which companies are challenging Lusedra (daprodustat), and what Paragraph IV litigation exists?
Featured snippet answer: No litigation parties, case numbers, or filing/decision dates are available in the supplied context.
What to extract from each PIV case
A litigation-ready matrix requires:
- Challenger name(s)
- FDA submission date
- PIV filing date
- Asserted Orange Book patents
- Court(s) and case numbers
- Status: motion to dismiss, Markman, summary judgment, injunction, appeal
- Settlement agreement terms and expected launch dates
How does Lusedra compare with other HIF-PHI competitors on clinical outcomes and launch risk?
Featured snippet answer: No competitor list, trial head-to-head results, or commercial timelines are provided in the supplied context.
Comparison axes used in HIF-PHI market intelligence
- Hemoglobin control magnitude and durability
- Transfusion reduction
- Safety outcomes and event rates
- Label differentiation (dialysis vs non-dialysis)
- Dosing convenience and formulary adoption patterns
What formulations are protected for Lusedra (daprodustat) and what generic entry risks exist?
Featured snippet answer: No formulation patent numbers or dosage-strength mapping are provided in the supplied context.
Common formulation/IP barriers for small-molecule anemia drugs
Generic risk increases when patents cover:
- Specific tablet core composition and excipient selection
- Coatings and release profiles
- Stability and manufacturing-specific process parameters
- Particle size and solid-state properties (polymorph-specific)
How generic entry risk is modeled
A robust risk model requires:
- Whether the generic can “design around” method-of-use patents
- Whether it must match a protected release profile or composition claims
- Whether bioequivalence can be achieved without infringing formulation claims
What FDA regulatory milestones apply to Lusedra (daprodustat), and what is the current label scope?
Featured snippet answer: No FDA milestone dates or label scope details are provided in the supplied context.
Milestone elements needed for projection
Projection inputs require:
- Approval date(s)
- Any supplemental approvals expanding indication populations
- Changes in dosing, contraindications, or REMS (if any)
- Postmarketing commitments affecting label updates
Clinical-trial update to market impact: what drives adoption for Lusedra (daprodustat) in CKD anemia?
Featured snippet answer: No adoption metrics, payer coverage data, or prescribing trends are provided in the supplied context.
Adoption drivers typically used in CKD anemia forecasting
- Kidney specialty and dialysis unit formularies
- ESA versus HIF-PHI switching rates
- Patient-specific risk profile (transfusion history, ESA responsiveness)
- Payer prior authorization dynamics and step therapy
- Safety communications and label updates
Revenue projection for Lusedra (daprodustat): exclusivity window, competitive pressure, and scenario modeling
Featured snippet answer: A defensible revenue projection cannot be produced from the supplied context without market size data, uptake curves, pricing assumptions, and exclusivity/patent timing.
What a projection model needs for daprodustat
A launch- and exclusivity-driven model requires:
- Current net sales baseline and channel mix
- Expected volume growth by dialysis status
- Price erosion assumptions by segment
- Competitive set and entry timing (generics and/or other branded HIF-PHI)
- Patent expiration and settlement-based generic launch calendars
- Forecast horizon tied to specific patent expirations and FDA approval milestones
Key Takeaways
- A complete, accurate clinical-trials update, Orange Book status, patent-exclusivity timeline, and litigation-driven market projection for Lusedra cannot be generated from the information provided.
- High-stakes projection work for daprodustat depends on enumerated patent numbers, mapped jurisdictions, FDA milestones, and current litigation posture, none of which are present in the supplied context.
- Any attempt to fill these gaps would risk incorrect patent dates, trial statuses, and exclusivity windows, which are decision-critical for R&D, licensing, and investment planning.
FAQs
- What determines generic launch timing for daprodustat besides patent expiration?
- How do dialysis versus non-dialysis CKD labels change competitive uptake for HIF-PHIs?
- Which endpoints most influence payer coverage decisions for CKD anemia therapies like daprodustat?
- How are method-of-use and formulation patents typically distinguished for small-molecule anemia drugs?
- What settlement terms in Paragraph IV cases most affect “no-early-entry” dates?
References
- (No sources were provided in the prompt to cite.)
